A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma

BACKGROUND: Smoldering multiple myeloma (SMM) is an indolent disease stage, considered to represent the transition phase from the premalignant MGUS (Monoclonal Gammopathy of Undetermined Significance) state towards symptomatic multiple myeloma (MM). Even though this diagnosis provides an opportunity...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Main Authors: Wichert, Stina, Juliusson, Gunnar, Johansson, Åsa, Sonesson, Elisabeth, Teige, Ingrid, Wickenberg, Anna Teige, Frendeus, Björn, Korsgren, Magnus, Hansson, Markus
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2017
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5291423/
https://ncbi.nlm.nih.gov/pubmed/28158311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0171205
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares